435 related articles for article (PubMed ID: 27262707)
21. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
22. Erythrodermic CTCL: updated clues to diagnosis and treatment.
Bernengo MG; Quaglino P
G Ital Dermatol Venereol; 2012 Dec; 147(6):533-44. PubMed ID: 23149699
[TBL] [Abstract][Full Text] [Related]
23. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
25. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
26. Genotypic analysis of cutaneous T-cell lymphoma: a comparative study of Southern blot analysis with polymerase chain reaction amplification of the T-cell receptor-gamma gene.
Curcó N; Servitje O; Llucià M; Bertran J; Limón A; Carmona M; Romagosa V; Peyrí J
Br J Dermatol; 1997 Nov; 137(5):673-9. PubMed ID: 9415223
[TBL] [Abstract][Full Text] [Related]
27. Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.
Gallardo F; Bertran J; López-Arribillaga E; González J; Menéndez S; Sánchez I; Colomo L; Iglesias M; Garrido M; Santamaría-Babí LF; Torres F; Pujol RM; Bigas A; Espinosa L
Leukemia; 2018 Oct; 32(10):2211-2223. PubMed ID: 29511289
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas.
Bakels V; van Oostveen JW; van der Putte SC; Meijer CJ; Willemze R
Am J Pathol; 1997 Jun; 150(6):1941-9. PubMed ID: 9176388
[TBL] [Abstract][Full Text] [Related]
29. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
[TBL] [Abstract][Full Text] [Related]
30. [Malignant lymphoma of the skin].
Burg G; Dommann S; Dummer R
Ther Umsch; 1993 Dec; 50(12):828-34. PubMed ID: 8171405
[TBL] [Abstract][Full Text] [Related]
31. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
[TBL] [Abstract][Full Text] [Related]
33. Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
Ion A; Popa IM; Papagheorghe LM; Lisievici C; Lupu M; Voiculescu V; Caruntu C; Boda D
Dis Markers; 2016; 2016():9602472. PubMed ID: 27821903
[TBL] [Abstract][Full Text] [Related]
34. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma.
Shen X; Wang B; Li K; Wang L; Zhao X; Xue F; Shi R; Zheng J
J Invest Dermatol; 2018 Sep; 138(9):2024-2032. PubMed ID: 29559342
[TBL] [Abstract][Full Text] [Related]
36. Histopathology and genetics of cutaneous T-cell lymphoma.
Smoller BR; Santucci M; Wood GS; Whittaker SJ
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1277-311. PubMed ID: 14710885
[TBL] [Abstract][Full Text] [Related]
37. Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders.
Maurus K; Appenzeller S; Roth S; Brändlein S; Kneitz H; Goebeler M; Rosenwald A; Geissinger E; Wobser M
J Invest Dermatol; 2020 Oct; 140(10):2023-2031.e1. PubMed ID: 32147503
[TBL] [Abstract][Full Text] [Related]
38. Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.
Park J; Daniels J; Wartewig T; Ringbloom KG; Martinez-Escala ME; Choi S; Thomas JJ; Doukas PG; Yang J; Snowden C; Law C; Lee Y; Lee K; Zhang Y; Conran C; Tegtmeyer K; Mo SH; Pease DR; Jothishankar B; Kwok PY; Abdulla FR; Pro B; Louissaint A; Boggon TJ; Sosman J; Guitart J; Rao D; Ruland J; Choi J
Blood; 2021 Oct; 138(14):1225-1236. PubMed ID: 34115827
[TBL] [Abstract][Full Text] [Related]
39. T-cell technology in the diagnosis & management of cutaneous T-cell lymphoma.
Duncan KO; Heald PW
Compr Ther; 1998 Mar; 24(3):117-22. PubMed ID: 9559245
[TBL] [Abstract][Full Text] [Related]
40. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
